The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was <4 ng/ml. Eight patients (33%) only had a subjective response. However, 75% of the patients with a PSA value <4 ng/ml had a subjective improvement. On the other hand, subjective response was 25% only in patients in whom PSA value decreased to <50% of the initial value but >4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.

Serretta, V., Rizzo, I., Contino, G., Pavone, C., Pomara, G., Melloni, D., et al. (2001). PSA and second-line therapy of hormone refractory prostate carcinoma. UROLOGIA INTERNATIONALIS, 66, 131-134 [10.1159/000056591].

PSA and second-line therapy of hormone refractory prostate carcinoma

SERRETTA, Vincenzo;PAVONE, Carlo;POMARA, Giuseppe;MELLONI, Darvinio;
2001

Abstract

The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was <4 ng/ml. Eight patients (33%) only had a subjective response. However, 75% of the patients with a PSA value <4 ng/ml had a subjective improvement. On the other hand, subjective response was 25% only in patients in whom PSA value decreased to <50% of the initial value but >4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.
Settore MED/24 - Urologia
http://www.karger.com/Article/Abstract/56591
Serretta, V., Rizzo, I., Contino, G., Pavone, C., Pomara, G., Melloni, D., et al. (2001). PSA and second-line therapy of hormone refractory prostate carcinoma. UROLOGIA INTERNATIONALIS, 66, 131-134 [10.1159/000056591].
File in questo prodotto:
File Dimensione Formato  
Urol Int 2001 66 131 134.pdf

Solo gestori archvio

Descrizione: articolo in extenso
Dimensione 2.47 MB
Formato Adobe PDF
2.47 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/201359
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact